HONG KONG, May 21, 2025 – We are thrilled to announce that today, May 21, 2025, Eagle IP celebrates its 20th anniversary, marking two decades of dedication to client success and innovation in patent law. Founded on May 21, 2005 by Dr. Jacqueline Lui (Jackie), the firm has grown from its humble beginnings into a respected name in the industry.

In a recent team celebration, Jackie, the firm’s founder, shared her reflections on Eagle IP’s journey. “Starting Eagle IP was a leap of faith driven by my commitment to my clients and their patent portfolios,” she said. “Transferring two significant portfolios laid the foundation for the beginnings of the firm and paved the way towards our success. I’m grateful for the perseverance that carried us through tough times. Our CPR culture—caring, professional, and responsive—has defined who we are and will guide us forward.”

The anniversary event highlighted the firm’s strong culture, with team members who have been with the firm for over a decade sharing memories of growth under Jackie’s leadership.

Jennifer Che, current President and Managing Director who “took the baton” of Eagle IP leadership last year from Jackie, expressed her commitment to upholding these values while driving expansion, noting the firm’s increasing client base and active participation in global conferences.

Eagle IP looks to the future with optimism, dedicated to maintaining its high standards, fostering continuous learning, and building stronger team relationships. Jackie and her husband HC Lui emphasized the power of teamwork, assuring continued support as the firm embarks on its next chapter.

A huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”?

2025年5月28日
The Impact of Parameter Features on Inventiveness ”Parameter features” – numerical or mathematical expressions that define the quantity or physical properties of a subject – frequently appear as technical features within a claim. Often described as numerical ranges or measurements, they frequently play a critical role in addressing technical problems. However, in practice, Examiners and […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right